Eiji Kiyohara

Dr. Eiji Kiyohara

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
YKYoun H Kim
Youn H Kim
MBMartine Bagot
Martine Bagot
LPLauren Pinter-Brown
Lauren Pinter-Brown
ARAlain H Rook
Alain H Rook
PPPierluigi Porcu
Pierluigi Porcu
KYKentaro Yonekura
Kentaro Yonekura

1 October 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PDF file
LLLaurent Lessard
Laurent Lessard
MLMichelle Liu
Michelle Liu
DMDiego M. Marzese
Diego M. Marzese
HWHongwei Wang
Hongwei Wang
KCKelly Chong
Kelly Chong
DHDave Hoon
Dave Hoon
In recent years, considerable advances have been made in the characterization of protein-coding alterations involved in the pathogenesis of melanoma. However, despite their growing implication in cancer, little is known about the role of long noncoding RNAs in melanoma progression. We hypothesized that copy number alterations (CNAs) of intergenic nonprotein-coding domains could help identify long intergenic noncoding RNAs (lincRNAs) associated with metastatic cutaneous melanoma. Among several candidates, our approach uncovered the chromosome 6p22.3 CASC15 (cancer susceptibility candidate 15) lincRNA locus as a frequently gained genomic segment in metastatic melanoma tumors and cell lines. The locus was actively transcribed in metastatic melanoma cells, and upregulation of CASC15 expression was associated with metastatic progression to brain metastasis in a mouse xenograft model. In clinical specimens, CASC15 levels increased during melanoma progression and were independent predictors of disease recurrence in a cohort of 141 patients with AJCC (American Joint Committee on Cancer) stage III lymph node metastasis. Moreover, small interfering RNA (siRNA) knockdown experiments revealed that CASC15 regulates melanoma cell phenotype switching between proliferative and invasive states. Accordingly, CASC15 levels correlated with known gene signatures corresponding to melanoma proliferative and invasive phenotypes. These findings support a key role for CASC15 in metastatic melanoma.

6 September 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
DMDiego M. Marzese
Diego M. Marzese
Richard A ScolyerRichard A Scolyer
Richard A Scolyer
JHJamie L. Huynh
Jamie L. Huynh
SHSharon K. Huang
Sharon K. Huang
HHHajime Hirose
Hajime Hirose
DHDave Hoon
Dave Hoon
Melanoma brain metastasis (MBM) represents a frequent complication of cutaneous melanoma. Despite aggressive multi-modality therapy, patients with MBM often have a survival rate of <1 year. Alteration in DNA methylation is a major hallmark of tumor progression and metastasis; however, it remains largely unexplored in MBM. In this study, we generated a comprehensive DNA methylation landscape through the use of genome-wide copy number, DNA methylation and gene expression data integrative analysis of melanoma progression to MBM. A progressive genome-wide demethylation in low CpG density and an increase in methylation level of CpG islands according to melanoma progression were observed. MBM-specific partially methylated domains (PMDs) affecting key brain developmental processes were identified. Differentially methylated CpG sites between MBM and lymph node metastasis (LNM) from patients with good prognosis were identified. Among the most significantly affected genes were the HOX family members. DNA methylation of HOXD9 gene promoter affected transcript and protein expression and was significantly higher in MBM than that in early stages. A MBM-specific PMD was identified in this region. Low methylation level of this region was associated with active HOXD9 expression, open chromatin and histone modifications associated with active transcription. Demethylating agent induced HOXD9 expression in melanoma cell lines. The clinical relevance of this finding was verified in an independent large cohort of melanomas (n = 145). Patients with HOXD9 hypermethylation in LNM had poorer disease-free and overall survival. This epigenome-wide study identified novel methylated genes with functional and clinical implications for MBM patients.

28 August 2014 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
DMDiego M. Marzese
Diego M. Marzese
MLMichelle Liu
Michelle Liu
JHJamie L. Huynh
Jamie L. Huynh
HHHajime Hirose
Hajime Hirose
NDNicholas C. Donovan
Nicholas C. Donovan
DHDave Hoon
Dave Hoon

1 June 2014 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
CCConnie G Chiu
Connie G Chiu
YNYoshitaka Nakamura
Yoshitaka Nakamura
KCKelly K Chong
Kelly K Chong
SHSharon K Huang
Sharon K Huang
NKNeal P Kawas
Neal P Kawas
DHDave Hoon
Dave Hoon
BACKGROUND: Circulating tumor cells (CTC) have been found in patients with metastatic melanoma and are associated with advanced melanoma stage and poor patient outcome. We hypothesize that CTC harbor genomic changes critical in the development of distant systemic metastasis. Here, we present the first genome-wide copy-number aberration (CNA) and loss of heterozygosity (LOH)-based characterization of melanoma CTC. METHODS: CTC were isolated from peripheral blood monocytes of 13 melanoma patients with regional metastasis stage IIIB/C using antibodies against melanoma-associated cell surface gangliosides. RESULTS: We characterized 251 CNA in CTC. Comparative analysis demonstrated >90% concordance in single-nucleotide polymorphism profiles between paired CTC and tumor metastases. In particular, there were notable recurring CNA across patients. In exploratory studies, the presence of several top CTC-associated CNA was verified in distant metastasis (stage IV) from 27 patients, suggesting that certain genomic changes are propagated from regional metastasis to CTC and to distant systemic metastases. Lastly, an exploratory biomarker panel derived from 5 CTC-associated CNA [CSMD2 (CUB and Sushi multiple domains 2), 1p35.1; CNTNAP5 (contactin associated protein-like 5), 2q14.3; NRDE2 (NRDE-2, necessary for RNA interference, domain containing), 14q32.11; ADAM6 (ADAM metallopeptidase domain 6, pseudogene), 14q32.33; and TRPM2 (transient receptor potential cation channel, subfamily m, member 2), 21q22.3] conferred prognostic utility for melanoma recurrence [hazard ratio (HR), 1.14; CI, 1.00–1.44; P = 0.0471] and death (HR, 2.86; CI, 1.23–14.42; P = 0.0014) in 35 patients with stage IIIB/C melanoma, with a 5-year disease-free survival of 13% vs 69% (P = 0.0006) and overall survival of 28% vs 94% between high-risk and low-risk groups defined by the biomarker panel, respectively. CONCLUSIONS: This study provides the first detailed CNA-based profile of melanoma CTC and illustrates how CTC may be used as a novel approach for identification of systemic metastasis.

8 September 2011 in Gene Therapy
Verified
Journal Article
Closed access
EKEiji Kiyohara
Eiji Kiyohara
KTK Tamai
K Tamai
IKI Katayama
I Katayama
YKY Kaneda
Y Kaneda